Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.54 USD
Change Today +0.019 / 3.65%
Volume 1.2M
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (STEM) Snapshot

Open
$0.50
Previous Close
$0.52
Day High
$0.57
Day Low
$0.49
52 Week High
09/5/14 - $1.53
52 Week Low
08/24/15 - $0.31
Market Cap
58.5M
Average Volume 10 Days
743.5K
EPS TTM
$-0.40
Shares Outstanding
108.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for STEMCELLS INC (STEM)

stemcells inc (STEM) Related Businessweek News

No Related Businessweek News Found

stemcells inc (STEM) Details

StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system. The company has completed Phase I/II clinical trial for the treatment of chronic spinal cord injury; and Phase I clinical trial for the treatment of Pelizaeus-Merzbacher disease, as well as completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration that cause blindness in the elderly. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

69 Employees
Last Reported Date: 03/13/15
Founded in 1988

stemcells inc (STEM) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $789.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $607.5K
Executive Vice President of Scientific & Stra...
Total Annual Compensation: $457.3K
General Counsel and Secretary
Total Annual Compensation: $409.6K
Compensation as of Fiscal Year 2014.

stemcells inc (STEM) Key Developments

StemCells Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

StemCells Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $30,000 compared to $23,000 a year ago. Loss from operations was $9,273,000 compared to $7,960,000 a year ago. Net loss was $8,462,000 or $0.09 per basic and diluted share compared to $12,115,000 or $0.22 per basic and diluted share a year ago. Net loss from continuing operations was $8,462,000 against $1,971,000 a year ago. Revenue from continuing operations is primarily from royalties received under various licensing agreements. For the six months, the company reported total revenue of $51,000 compared to $47,000 a year ago. Loss from operations was $18,233,000 compared to $14,802,000 a year ago. Net loss was $17,812,000 or $0.22 per basic and diluted share compared to $19,735,000 or $0.36 per basic and diluted share a year ago. Net loss from continuing operations was $17,812,000 against $19,533,000 a year ago.

StemCells Inc. to Report Q2, 2015 Results on Aug 06, 2015

StemCells Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 06, 2015

StemCells Inc., Q2 2015 Earnings Call, Aug 06, 2015

StemCells Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $0.54 USD +0.019

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.14 USD +0.01
Bioheart Inc $0.0034 USD 0.00
Biorestorative Therapies Inc $7.49 USD +0.49
Cytori Therapeutics Inc $0.36 USD -0.0129
Opexa Therapeutics Inc $0.44 USD +0.0195
View Industry Companies
 

Industry Analysis

STEM

Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 48.7x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit www.stemcellsinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.